“Making TauRx’s groundbreaking drug HMTM# accessible to patients with Alzheimer's Disease under Named Patient Program”
HONG KONG SAR / SINGAPORE -
Media OutReach Neswire - 18 January 2024 - ICB Medical Ltd ("
ICB"), a member of the Immuno Cure BioTech Group ("
Immuno Cure"), is appointed as the exclusive Named Patient Program ("
NPP") Manager, for TauRx's groundbreaking drug, Hydromethylthionine Mesylate ("
HMTM#"), in Hong Kong SAR and Macau SAR ("
Territories") by Poredeen Pte Ltd ("
Poredeen"), a wholly owned subsidiary within the TauRx Pharmaceuticals Ltd group of companies ("TauRx").
Read more: Poredeen Appoints ICB as Exclusive Named Patient Program Manager for HMTM# in Hong Kong and Macau